- Home
- PHYS vs ROIV Comparison
PHYS vs ROIV Comparison
Compare PHYS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHYS
- ROIV
- Stock Information
- Founded
- PHYS N/A
- ROIV 2014
- Country
- PHYS
- ROIV United Kingdom
- Employees
- PHYS N/A
- ROIV N/A
- Industry
- PHYS
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- PHYS
- ROIV Health Care
- Exchange
- PHYS NYSE
- ROIV Nasdaq
- Market Cap
- PHYS 8.5B
- ROIV 8.8B
- IPO Year
- PHYS N/A
- ROIV N/A
- Fundamental
- Price
- PHYS $20.20
- ROIV $11.57
- Analyst Decision
- PHYS
- ROIV Strong Buy
- Analyst Count
- PHYS 0
- ROIV 8
- Target Price
- PHYS N/A
- ROIV $17.93
- AVG Volume (30 Days)
- PHYS N/A
- ROIV 5.3M
- Earning Date
- PHYS N/A
- ROIV 02-11-2025
- Dividend Yield
- PHYS N/A
- ROIV N/A
- EPS Growth
- PHYS N/A
- ROIV N/A
- EPS
- PHYS N/A
- ROIV 5.89
- Revenue
- PHYS N/A
- ROIV $129,128,999.00
- Revenue This Year
- PHYS N/A
- ROIV $15.98
- Revenue Next Year
- PHYS N/A
- ROIV N/A
- P/E Ratio
- PHYS N/A
- ROIV $2.06
- Revenue Growth
- PHYS N/A
- ROIV 145.68
- 52 Week Low
- PHYS N/A
- ROIV $9.69
- 52 Week High
- PHYS N/A
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- PHYS 45.98
- ROIV 41.56
- Support Level
- PHYS $20.17
- ROIV $11.72
- Resistance Level
- PHYS $20.98
- ROIV $12.22
- Average True Range (ATR)
- PHYS 0.16
- ROIV 0.30
- MACD
- PHYS -0.03
- ROIV -0.09
- Stochastic Oscillator
- PHYS 27.98
- ROIV 15.24
About PHYS SPROTT PHYSICAL GOLD TRUST
Sprott Physical Gold Trust is a closed-end mutual fund trust. The company provides a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical gold bullion without the inconvenience associated with direct investment in physical gold bullion. The company invests mainly in long-term holdings of unencumbered, fully allocated, physical gold bullion and does not and will not speculate about short-term changes in gold prices.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.